XPRIZE hands $1m to a mitochondrial drug team
Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older adults. Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology
<p>Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older adults. Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology</p>